TARO — Taro Pharmaceutical Industries Balance Sheet
0.000.00%
Last trade - 00:00- $1.59bn
- $691.48m
- $572.95m
- 98
- 54
- 89
- 94
Annual balance sheet for Taro Pharmaceutical Industries, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,049 | 1,109 | 1,024 | 821 | 850 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 278 | 264 | 254 | 293 | 248 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1,483 | 1,533 | 1,471 | 1,338 | 1,336 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 206 | 212 | 208 | 205 | 194 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,135 | 2,341 | 2,407 | 2,176 | 2,136 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 217 | 223 | 676 | 432 | 386 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 230 | 237 | 703 | 465 | 405 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,906 | 2,104 | 1,704 | 1,711 | 1,731 |
| Total Liabilities & Shareholders' Equity | 2,135 | 2,341 | 2,407 | 2,176 | 2,136 |
| Total Common Shares Outstanding |